Related Experiment Video
Updated: Jan 22, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase
Zachary W Veitch1, David W Cescon1,2, Trisha Denny2
1Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Background:
CFI-400945 is a first-in-class oral inhibitor of polo-like kinase 4 (PLK4) that regulates centriole duplication. Primary objectives of this first-in-human phase 1 trial were to establish the safety and tolerability of CFI-400945 in patients with advanced solid tumours. Secondary objectives included pharmacokinetics, pharmacodynamics, efficacy, and recommended phase 2 dose (RP2D).
Methods:
Continuous daily oral dosing of CFI-400945 was evaluated using a 3+3 design guided by incidence of dose-limiting toxicities (DLTs) in the first 28-day cycle. Safety was assessed by CTCAE v4.0. ORR and CBR were evaluated using RECIST v1.1.
Results:
Forty-three patients were treated in dose escalation from 3 to 96 mg/day, and 9 were treated in 64 mg dose expansion. After DLT occurred at 96 and 72 mg, 64 mg was established as the RP2D. Neutropenia was a common high-grade (19%) treatment-related adverse event at ≥ 64 mg. Half-life of CFI-400945 was 9 h, with Cmax achieved 2-4 h following dosing. One PR (45 cycles, ongoing) and two SD ≥ 6 months were observed (ORR = 2%; CBR = 6%).
Conclusions:
CFI-400945 is well tolerated at 64 mg with dose-dependent neutropenia. Favourable pharmacokinetic profiles were achieved with daily dosing. Response rates were low without biomarker pre-selection. Disease-specific and combination studies are ongoing.
Trial Registration:
Clinical Trials Registration Number - NCT01954316 (Oct 1st, 2013).
Insights
CFI-400945, a novel polo-like kinase 4 inhibitor, demonstrated acceptable safety and tolerability in a phase 1 trial for advanced solid tumors. The recommended phase 2 dose is 64 mg daily, with neutropenia as a key adverse event.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- CFI-400945 is a first-in-class oral inhibitor targeting polo-like kinase 4 (PLK4), an enzyme crucial for centriole duplication.
- This study represents the first-in-human phase 1 clinical trial of CFI-400945 in patients with advanced solid tumors.
Purpose of the Study:
- To determine the safety and tolerability of CFI-400945 in patients with advanced solid tumors.
- To establish the recommended phase 2 dose (RP2D) and evaluate pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of CFI-400945.
Main Methods:
- A 3+3 dose escalation design was employed to evaluate continuous daily oral dosing of CFI-400945.
- Safety was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0, and efficacy was evaluated by Objective Response Rate (ORR) and Clinical Benefit Rate (CBR) per RECIST v1.1.
Main Results:
- A total of 43 patients received escalating doses from 3 to 96 mg/day, with 9 patients in the 64 mg dose expansion cohort.
- The recommended phase 2 dose (RP2D) was established at 64 mg/day after dose-limiting toxicities were observed at higher doses.
- Neutropenia was the most common high-grade treatment-related adverse event (19%) at doses ≥64 mg. The drug exhibited a half-life of 9 hours.
- Limited efficacy was observed, with an ORR of 2% and CBR of 6%, including one partial response and two cases of stable disease ≥6 months.
Conclusions:
- CFI-400945 at 64 mg/day is well-tolerated, with dose-dependent neutropenia as a primary toxicity.
- Favorable pharmacokinetic profiles were achieved with daily oral administration.
- Low response rates were observed in this unselected patient population, suggesting the need for biomarker-guided or combination studies.
Related Concept Videos
Dose-Response Relationship: Selectivity and Specificity
Phase Diagrams
Survey Safety
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Phase Transitions

![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)